Positive Response Observed in HS Patients Having Failed Anti|TNF ...

Positive Response Observed in HS Patients Having Failed Anti-TNF ...

Key Takeaways · Lutikizumab demonstrated higher response rates in HS patients unresponsive to anti-TNF therapy compared to placebo in a phase 2 ...

Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult ...

“In this hard-to-treat moderate-to-severe HS patient population that has failed anti-TNF therapy, lutikizumab300 mg every week and 300 mg every ...

Hidradenitis suppurativa: key insights into treatment success and ...

In line with this, recent phase II data in HS patients who had previously failed anti-TNF therapy demonstrated a promising clinical response to ...

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults ...

Higher response rates were also observed in patients ... patients with moderate to severe HS who had previously failed anti-TNF therapy.

23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A ...

Thirdly, anti-IL-23-treated patients showed higher rates of achieving a clinical response at 6 months compared with those treated with anti-IL- ...

Secukinumab in Hidradenitis Suppurativa Patients Who Failed ...

The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic ...

Secukinumab in patients with moderate-to-severe hidradenitis ...

In 2023, Kimball et al.14 reported the primary efficacy and safety results from the SUNSHINE and SUNRISE phase III clinical trials of secukinumab, a fully human ...

TNF-α inhibitors in the treatment of hidradenitis suppurativa

Initial evidence for the use of TNF-α inhibitors in HS stemmed from recognition that inflammatory bowel disease patients treated with these medications saw a ...

A Phase II Open-Label Study of Bermekimab in Patients with ...

A significant reduction in abscesses and inflammatory nodules of 60% (P < 0.004) and 46% (P < 0.001) was seen in anti-TNF naïve and anti-TNF failure groups, ...

Secukinumab Potentially Effective, Safe in Patients With HS Not ...

After 16 weeks, 48.9% of the 47 patients achieved a response based on Hidradenitis Suppurativa Clinical Response (HiSCR) criteria. Mean ...

Immune Dysregulation and Current Targeted Biologics in ... - MDPI

A 100% HiSCR response was observed at week 4 with weekly dosing, and in contrast to dosing every 2 weeks, no cyclical disease suppression or recurrence was ...

Ustekinumab in Hidradenitis Suppurativa: A Systematic Review and ...

In this systematic review and meta-analysis of ten articles with 88 patients, we found that the pooled response rate to ustekinumab was 67%. The ...

Treatment of Hidradenitis Suppurativa With Etanercept Injection

Three anti-TNF agents, etanercept, infliximab, and adalimumab, are currently being evaluated for use in HS therapy. Etanercept, a dimeric human TNF receptor ...

MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis ...

Clinical efficacy was maintained at 24 weeks in 0% and 40%. Improvement in the visual analog scale was reported by 20% and 85.7%, respectively, of patients ...

A novel treatment paradigm for hidradenitis suppurativa

Persistent inflammatory activity and purulent drainage observed in the majority of patients with ... Predictors of · response to anti-TNF-alpha therapy among ...

View of Efficacy and Safety of Risankizumab in Hidradenitis ...

Group 2 patients presented a lower IHS4 score at baseline due to good control during previous therapy with adalimumab and maintained HS control with further ...

Severe Hidradenitis Suppurativa Treated With Adalimumab

Although the pathogenesis of HS is not well understood, successful case reports of patients with HS responding to treatment with infliximab, which targets TNF, ...

Immunopathogenesis of hidradenitis suppurativa and ... - JCI Insight

Anti–TNF-α therapy markedly attenuated B cell activation with minimal effect on other inflammatory pathways. Finally, we identified an immune activation ...

Short-Term Effectiveness, Safety, and Potential Predictors of ...

48.9% (23/47) of patients achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at week 16, while 6.4% (3/47) of patients presented ...

New and Emerging Targeted Therapies for Hidradenitis Suppurativa

This drug should be administered if a patient with mild to moderate disease (Hurley stage I or II) fails to respond to the standard first- or second-line ...